07:00 , Apr 27, 2015 |  BC Week In Review  |  Company News

Northwestern University, Panther Biotechnology deal

Panther exercised a 2014 option to license exclusive, worldwide rights to the university’s numonafide . The preclinical candidate is a small molecule derivative of amonafide, a DNA intercalator and topoisomerase II (TOP2) inhibitor (see BioCentury,...
07:00 , Sep 15, 2014 |  BC Week In Review  |  Company News

Northwestern University, Panther Biotechnology deal

Panther received an option from the university to license exclusive, worldwide rights to numonafide . The preclinical cancer compound is a small molecule derivative of amonafide, a topoisomerase II (TOP) inhibitor and DNA intercalator. The...